-
by katehumphrey | Mar 27, 2024 3:15 pm | Biotechnology, Private Equity | 0 comments
Highbridge Capital Management, based in New York City, announced on March 27 that it entered into an agreement to acquire Gamida Cell, an Israeli biotechnology company. The agreement will see Highbridge Capital Management convert $75 million of existing unsecured convertible senior notes into equity in Gamida as well as supply $30 million... Read More » -
American Oncology Network Partners With Woodlands Cancer Institute
by Avery Swett | Mar 27, 2024 1:58 pm | Physician Medical Groups | 0 comments
The American Oncology Network (AON) announced on March 26 the addition of Woodlands Cancer Institute and its physicians to its network. Woodlands Cancer Institute is AON’s second practice in Texas and first in Montgomery County. Headquartered in The Woodlands, Texas, Woodlands Cancer Institute is a community-based radiation oncology and... Read More » -
Eisenhower Health Purchases Neuro Vitality Center
by Avery Swett | Mar 27, 2024 1:57 pm | Other Services | 0 comments
Rancho Mirage, California-based Eisenhower Health announced that it has purchased the Neuro Vitality Center in California. Neuro Vitality Center, formerly the Stroke Recovery Center, is a medical clinic that has served neurologically challenged and chronically ill patients in the Palm Springs, California community since 1978. In partnership with... Read More » -
StatLab Medical Products Acquires Poly Scientific R&D
by katehumphrey | Mar 26, 2024 1:45 pm | Laboratories, MRI & Dialysis, Private Equity | 0 comments
McKinney, Texas-based StatLab Medical Products announced that it has acquired Poly Scientific R&D. Poly Scientific is one of the leading manufacturers of chemicals, stains and reagents for histology, cytology and microbiology, as well as other items for in-vitro diagnostic testing. The company was founded in 1969 and is based in Bay... Read More » -
Juvisé Pharmaceuticals Purchases Global Rights to PONVORY
by katehumphrey | Mar 26, 2024 1:44 pm | Pharmaceuticals | 0 comments
On March 26, Juvisé Pharmaceuticals announced that it entered into an agreement to acquire the global rights to PONVORY from Actelion Pharmaceuticals, a Johnson & Johnson company. These global rights exclude the rights to United States and Canada. Ponvory is indicated for the treatment of adults with active forms of relapsing multiple... Read More »
Categories
- Ambulatory Surgery Centers
- Behavioral Health Care
- Biotechnology
- CDMO
- CRO
- eHealth
- Healthcare M&A News Leads
- Healthcare Market Updates
- Healthcare Staffing
- Home Health & Hospice
- Hospitals
- Laboratories, MRI & Dialysis
- Long-Term Care
- Managed Care
- Medical Devices
- Medical Office Buildings
- Occupational Health
- Other Services
- Pharmaceuticals
- Physician Medical Groups
- Private Equity
- Rehabilitation
- SPAC
- Specialty Pharmacies
- Uncategorized
- Urgent Care Centers